# A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

> **NCT05362110** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 361 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** HCP1803-3
- **DRUG:** RLD2002
- **DRUG:** HPP2003-3
- **DRUG:** HPP2004

## Key facts

- **NCT ID:** NCT05362110
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2023-06-05
- **Final completion:** 2023-06-05
- **Target enrollment:** 361 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05362110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05362110, "A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05362110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*